Chemoradiotherapy plus hyperthermia (CRTH) versus chemoradiotherapy (CRT) alone in neoadjuvant treatment of soft tissue sarcoma: tumor response, treatment toxicity and disease control

References

• Blay JY, Honoré C, Stoeckle E, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019;30(8):1407. doi: 10.1093/annonc/mdz170.
   PubMed Web of Science ®Google Scholar
• Jebsen NL, Trovik CS, Bauer HC, et al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian Sarcoma Group Study. Int J Radiat Oncol Biol Phys. 2008;71(4):1196–1203. doi: 10.1016/j.ijrobp.2007.11.023.
   PubMed Web of Science ®Google Scholar
• O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–2241. doi: 10.1016/S0140-6736(02)09292-9.
   PubMed Web of Science ®Google Scholar
• Gingrich AA, Bateni SB, Monjazeb AM, et al. Neoadjuvant radiotherapy is associated with R0 resection and improved survival for patients with extremity soft tissue sarcoma undergoing surgery: a national cancer database analysis. Ann Surg Oncol. 2017;24(11):3252–3263. doi: 10.1245/s10434-017-6019-8.
   PubMed Web of Science ®Google Scholar
• Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–1103. doi: 10.1016/s0959-8049(01)00083-1.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial [published correction appears in lancet oncol. Lancet Oncol. 2017;18(6):812–822. doi: 10.1016/S1470-2045(17)30334-0.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Wessalowski R, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2017;18(11):e630. doi: 10.1016/S1470-2045(10)70071-1.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483–492. doi: 10.1001/jamaoncol.2017.4996.
   PubMed Web of Science ®Google Scholar
• Hartmann JT. IAWS1/2, A cooperative investigation of the AIO, ARO and CAO to optimize either neo – or adjuvant treatment strategies adult patients with large sized, high grade non rhabdomyo (soft tissue) sarcoma (NRSTS) [accessed 2023 Aug 18]. Available from: https://haema-onko-cvk.charite.de/fileadmin/user_upload/microsites/m_cc14/haema-onko-cvk/Studien_Synopsen/Kunitz/Synopse_IAWS_1_und_2.pdf.
   Google Scholar
• Palassini E, Ferrari S, Verderio P, et al. Feasibility of preoperative chemotherapy With or Without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the italian sarcoma group/grupo español de investigación en sarcomas randomized clinical trial: three Versus five cycles of Full-Dose epirubicin Plus ifosfamide. J Clin Oncol. 2015;33(31):3628–3634. doi: 10.1200/JCO.2015.62.9394.
   PubMed Web of Science ®Google Scholar
• Stubbe F, Agaimy A, Ott O, et al. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: a single institutional experience. Cancer Radiother. 2016;20(1):6–13. doi: 10.1016/j.canrad.2015.05.032.
   PubMed Web of Science ®Google Scholar
• Eckert F, Braun LH, Traub F, et al. Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas. Int J Hyperthermia. 2018;34(7):980–987. doi: 10.1080/02656736.2017.1369174.
   PubMed Web of Science ®Google Scholar
• Sauer R, Schuchardt U, Hohenberger W, et al. Neoadjuvante radiochemotherapie von weichteilsarkomen. Optimierung der lokalen funktionserhaltenden tumorkontrolle [neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control]. Strahlenther Onkol. 1999;175(6):259–266. doi: 10.1007/BF02743576.
   PubMedGoogle Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol. 2011;187(10):605–610. doi: 10.1007/s00066-011-1145-x.
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol. 2012;188(Suppl 2):198–211. doi: 10.1007/s00066-012-0176-2.
   PubMed Web of Science ®Google Scholar
• Ott OJ, Gani C, Lindner LH, et al. Neoadjuvant chemoradiation combined with regional hyperthermia in locally advanced or recurrent rectal cancer. Cancers. 2021;13(6):1279. doi: 10.3390/cancers13061279.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. U.S. Department of Health and Human Services [accessed 2023 Kjul 6; published 2023 Nov 27]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
   Google Scholar
• O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878–1884. doi: 10.1002/cncr.27951.
   PubMed Web of Science ®Google Scholar
• Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671–680. doi: 10.1016/S1470-2045(16)00010-3.
   PubMed Web of Science ®Google Scholar
• Pasquali S, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial [published correction appears in cancer. Cancer. 2022;128(1):85–93. doi: 10.1002/cncr.33895.
   PubMed Web of Science ®Google Scholar
• Prosnitz LR, Maguire P, Anderson JM, et al. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys. 1999;45(4):941–949. doi: 10.1016/s0360-3016(99)00272-2.
   PubMed Web of Science ®Google Scholar
• D'Ambrosio L, Touati N, Blay JY, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the european organization for research and treatment of cancer soft tissue and bone sarcoma group. Cancer. 2020;126(11):2637–2647. doi: 10.1002/cncr.32795.
   PubMed Web of Science ®Google Scholar
• Martin-Broto J, Hindi N, Lopez-Pousa A, et al. Assessment of safety and efficacy of combined trabectedin and low-dose radiotherapy for patients With metastatic Soft-Tissue sarcomas: a nonrandomized phase 1/2 clinical trial [published correction appears in JAMA oncol. JAMA Oncol. 2020;6(4):535–541. doi: 10.1001/jamaoncol.2019.6584.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Hindi N, Cruz J, et al. Trabectedin and radiotherapy in soft tissue sarcoma (TRASTS): results of a phase I study in myxoid liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) sarcoma groups. EClinicalMedicine. 2019;9:35–43. doi: 10.1016/j.eclinm.2019.03.007.
   PubMedGoogle Scholar
• Weiss AR, Chen YL, Scharschmidt TJ, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(8):1110–1122. doi: 10.1016/S1470-2045(20)30325-9.
   PubMed Web of Science ®Google Scholar
• Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: radiation therapy oncology group trial 9514. J Clin Oncol. 2006;24(4):619–625. doi: 10.1200/JCO.2005.02.5577.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang Q, Eisenberg BL, et al. Significant reduction of late toxicities in patients With extremity sarcoma treated With Image-Guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial. J Clin Oncol. 2015;33(20):2231–2238. doi: 10.1200/JCO.2014.58.5828.
   PubMed Web of Science ®Google Scholar
• Potkrajcic V, Kolbenschlag J, Sachsenmaier S, et al. Postoperative complications and oncologic outcomes after multimodal therapy of localized high risk soft tissue sarcoma. Radiat Oncol. 2022;17(1):210. doi: 10.1186/s13014-022-02166-4.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and polish (PSG) sarcoma groups. J Clin Oncol. 2020;38(19):2178–2186. doi: 10.1200/JCO.19.03289.
   PubMed Web of Science ®Google Scholar